Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD), Ligand - LARVOL DELTA

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Comparison chart: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus

Invasive pneumococcal disease in Latin America: serotype distribution and vaccine coverage among adults in Mexico, Brazil, and Argentina. (PubMed, Vaccine) - "PCV21 offers substantially broader potential coverage for adult IPD than PCV20 and earlier-generation PCVs in Argentina, Brazil, and Mexico. If incorporated into adult immunization programs with sufficient uptake, PCV21 could meaningfully reduce IPD burden."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

A DOUBLE-BLIND, RANDOMIZED STUDY EVALUATING THE EFFICACY OF PCV15 IN PREVENTION OF ACUTE OTITIS MEDIA IN CHILDREN (V114-032): EFFICACY AGAINST PCV7 AND PCV13 SEROTYPES (ESPID 2026) - "The proportions of participants with SAEs were generally comparable between groups. Conclusions/Learning Points Results demonstrate PCV15 is efficacious in the prevention of AOM in infants and toddlers, and further suggest PCV15 sustains the progress achieved to date with pneumococcal disease prevention."

Clinical • Infectious Disease • Pneumococcal Infections

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=750 | Recruiting | Sponsor: GlaxoSmithKline | Trial primary completion date: Jul 2026 ➔ Nov 2026

Trial primary completion date • Infectious Disease • Varicella Zoster

A DOUBLE-BLIND, MULTI-SITE, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF PCV15 IN THE PREVENTION OF ACUTE OTITIS MEDIA (AOM) IN INFANTS AND TODDLERS (PNEU-ERA) (ISPPD 2026) - "PCV15 is efficacious in preventing AOM in infants and toddlers. Results align with precedent from lower-valency PCVs and support prevention of mucosal pneumococcal disease by PCV15."

Clinical • Late-breaking abstract • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia

PNEUMOCOCCAL PNEUMONIA EPIDEMIOLOGY, URINE SEROTYPING, MENTAL OUTCOMES (PNEUMO) STUDIES: A MULTI COUNTRY NETWORK TO UNDERSTAND THE BURDEN OF PNEUMOCOCCAL PNEUMONIA AND ASSOCIATED STREPTOCOCCUS PNEUMONIAE SEROTYPES (ISPPD 2026) - "Conclusions Pneumococcal CAP serotype distribution in adults is poorly understood. Results from the network of PNEUMO studies will yield robust results clarifying etiology of pneumonia in hospitalized adults and demonstrating the most common S pneumoniae serotypes associated with adult hospitalized pneumococcal CAP."

Clinical • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Economic Evaluation of PCV21 Use in Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction Threshold Analysis. (PubMed, Infect Dis Ther) - "For populations experiencing moderate increases in the proportion of ST4 (i.e., < 30%), PCV21 may offer health and economic benefits over PCV20 for US adults aged 19-64 years with underlying medical conditions. However, in populations with ≥ 30% ST4, ST4-containing vaccines should be used as per ACIP guidance."

HEOR • Journal • Infectious Disease • Pneumococcal Infections

Serotype distribution and coverage by pneumococcal vaccines in hospitalised adults with pneumococcal pneumonia in Germany. (PubMed, ERJ Open Res) - "Among adults hospitalised with CAP in Germany, S. pneumoniae was detected in 13% of cases by SSUAD assays. While the findings suggest that V116 may offer broader serotype coverage compared with PCV20, these differences were not statistically significant."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

VACCINE EFFECTIVENESS OF PCV15 AMONGST SWEDISH CHILDREN (ISPPD 2026) - "The 10 valent pneumococcal conjugate vaccine (PCV10) was replaced by PCV15 (which includes additional serotypes 3, 6A, 19A, 22F and 33F) in the Swedish child immunization program in 2023...This study also aims to study the VE of PCV15 on all-cause acute otitis media (AOM) and the impact of the PCV15 vaccination program.Methods This population-based, longitudinal observational study in Sweden includes children under 5 years of age, using national and regional registers to collect data from 2015 to December 2027. Main health outcomes include IPD and all-cause AOM.Results Results are expected by 2028.Conclusions To our knowledge this is the first study evaluating the effectiveness and impact of PCV15 in children."

Clinical • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia

A SUBGROUP ANALYSIS OF A PHASE 3, RANDOMIZED TRIAL INVESTIGATING SAFETY AND IMMUNOGENICITY OF V116 IN VACCINE-NAÏVE ADULTS AT INCREASED RISK OF PNEUMOCOCCAL DISEASE (STRIDE-8) (ISPPD 2026) - "The overall safety profile was comparable between groups.Conclusions In pneumococcal vaccine-naïve adults with chronic medical conditions, V116 was well tolerated and immunogenic compared to PCV15+PPSV23, regardless of the subgroup evaluated. V116 has the potential to broaden disease coverage in this vulnerable population."

Clinical • P3 data • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases

SEROTYPE DISTRIBUTION AND VACCINE COVERAGE BY RISK STATUS AMONG U.S. ADULTS HOSPITALIZED WITH COMMUNITY‑ACQUIRED PNEUMONIA, 2018–2022 (ISPPD 2026) - "Conclusions Most serotypes detected in all three patient risk groups were included in PCV21. Almost 40% of pneumococcal serotypes detected were unique to PCV21."

Clinical • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

INVASIVE PNEUMOCOCCAL DISEASE (IPD) AND SEROTYPE DISTRIBUTION AMONG CHILDREN WITH AND WITHOUT COMORBID CONDITIONS IN FINLAND IN 2015–2023 (ISPPD 2026) - "The Finnish national vaccination program has included the 10-valent pneumococcal conjugate vaccine (PCV10) since 2010 and is switching to the 13-valent vaccine (PCV13) during 2025–26.Methods We studied nationwide health register data on IPD, hospitalizations, and reimbursement entitlements for chronic conditions from Jan-2015 until Dec-2023...Conclusions Among children with non-PCV15-type IPD, the median LOS was longer in children with comorbidities than in those without (p=0.03). The serotype coverage of PCV15 and the 21-valent PCV were 78% and 89%, respectively, among all children with IPD."

Clinical • Immunology • Infectious Disease • Pneumococcal Infections • Pulmonary Disease • Respiratory Diseases

SEROTYPE DISTRIBUTION OF PNEUMOCOCCAL COMMUNITY-ACQUIRED PNEUMONIA IN HOSPITALIZED ADULTS IN SPAIN, FRANCE AND ITALY DURING THE SARS-COV-2 PANDEMIC (ISPPD 2026) - "These SSUAD assays combined, include all serotypes in PCV15, PCV20 and PCV21(V116)... In hospitalized adults with CAP in Spain, Italy and France during the SARS-CoV-2 pandemic, S. pneumoniae was detected in 21% of cases by all diagnostic tests. Considering documented serotypes, during this period, the potential coverage proportion of PCV21 was broader (92.5%) compared with earlier pneumococcal conjugate vaccines (75.4 and 51.7%)."

Clinical • Late-breaking abstract • Infectious Disease • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | N=354 ➔ 900

Enrollment change • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=1840 | Recruiting | Sponsor: GlaxoSmithKline | N=199 ➔ 1840

Enrollment change • Infectious Disease • Varicella Zoster

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=750 | Recruiting | Sponsor: GlaxoSmithKline | N=385 ➔ 750

Enrollment change • Infectious Disease • Varicella Zoster

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1092 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Streptococcus pneumoniae nasopharyngeal carriage in Vietnamese children during the first five years of life: a post hoc analysis. (PubMed, Lancet Reg Health West Pac) - "Serotype coverage was similar across products Pneumosil (68·6% [95% CI 65·5-71·7%], 595/867), Prevenar13 (70·0% [95% CI 67·0-73·1%], 607/867), and Vaxneuvance (70·0% [95% CI 67·0-73·1%], 607/867), and lower for Synflorix (41·5% [95% CI 38·2-44·8%], 360/867) p < 0·05 vs Pneumosil, Prevenar13 or Vaxneuvance...Serotype, lineage distribution, and prevalence of AMR genes across the sampled age groups remained consistent, indicating that these distributions are broadly representative of young unvaccinated children, helping to guide optimal approaches for pneumococcal surveillance in low- and middle-income countries. National Health and Medical Research Council, Bill & Melinda Gates Foundation, Murdoch Children's Research Institute."

Journal • Retrospective data • Infectious Disease • Pneumococcal Infections • Pneumonia

A Cost-Effectiveness Analysis of PCV21 Use in Vaccine-Experienced Adults Aged ≥65 Years in the US. (PubMed, Am J Prev Med) - "In the US, a dose of PCV21 in adults aged ≥65 years who have previously received a pneumococcal vaccine has the potential to prevent a considerable number of pneumococcal disease cases and deaths while remaining economically reasonable over a wide range of inputs and scenarios."

HEOR • Journal • Infectious Disease • Pneumococcal Infections

MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) - P=N/A | N=4 | Terminated | Sponsor: Montefiore Medical Center | N=45 ➔ 4 | Recruiting ➔ Terminated; Termination of funding by the sponsor/funder.

Enrollment change • Trial termination • Infectious Disease • Pneumococcal Infections • Transplantation

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites. (PubMed, Vaccines (Basel)) - P3 | "V114 was well tolerated and immunogenic for the 15 serotypes in V114 when administered either alone or followed by PPSV23. Use of V114 has the potential to expand serotype coverage and protect against pneumococcal disease resulting from serotypes absent in PCV13 among American Indian adults."

Journal • P3 data • Infectious Disease • Pneumococcal Infections • Pneumonia

V114 and Acute Otitis Media (V114-032/PNEU-ERA) (clinicaltrials.gov) - P3 | N=7118 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Otorhinolaryngology

Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus pneumoniae serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in the UK (RATIONALE-15). (PubMed, BMJ Open) - P4 | "The study is approved by the NHS Research and Ethics Committee (Reference: 24/SC/0388) and by the Medicines and Healthcare Products Regulatory Agency (Reference: CTA 21584/0485/001-0001). NCT06731374 - ISRCTN91656864."

Clinical protocol • Journal • P4 data • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness Analysis of Pediatric and Adult Pneumococcal Conjugate Vaccine Strategies in Canada (ISPOR-EU 2025) - "OBJECTIVES: In Canada, PCV15 (Vaxneuvance) and PCV20 (Prevnar 20) are approved for use in adult and pediatric populations... Funding PCV20 for both pediatric and adult public immunization programs could result in greater health and economic gains than funding PCV15 in pediatric and PCV21 in adult programs. Additionally, using one vaccine for all ages could enhance equity, simplify vaccine procurement, and improve logistical inefficiencies related to training, supply, and storage."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases